Although we characterized prognostic indicators for glioblastoma, IDH1/2-mutant astrocytoma, and oligodendroglioma, we were unable to comprehensively analyze molecular features for the pediatric-type and other IDH1/2-wild-type gliomas given the small sample sizes. This evidence concerns the gene IDH1 and central nervous system cancer.